A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Must have received: systemic therapy

Stage ≥Ib CTCL, which has relapsed or progressed after at least two systemic therapies

Must have received: brentuximab vedotin-containing therapy (brentuximab vedotin)

Systemic anaplastic large cell lymphoma that has relapsed after therapy containing brentuximab vedotin

Must have received: any prior therapy

For the following histologies, patients are required to have received at least 1 prior therapy: T-cell large granular lymphocytic leukemia, Aggressive NK-cell leukemia, Adult T-cell leukemia/lymphoma, Extranodal NK/T-cell lymphoma, nasal type, Enteropathy-associated T-cell lymphoma, Monomorphic epitheliotropic intestinal T-cell lymphoma, Hepatosplenic T cell lymphoma, Subcutaneous panniculitis-like T-cell lymphoma, Primary cutaneous anaplastic large cell lymphoma, Primary cutaneous gamma/delta T-cell lymphoma, Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma, Peripheral T-cell lymphoma, not otherwise specified, Angioimmunoblastic T cell lymphoma, Follicular T-cell lymphoma, Nodal peripheral T-cell lymphoma with T follicular helper phenotype

Cannot have received: allogeneic stem cell transplant

Exception: allowed after discussion with MSK PI if no GVHD or immunosuppression is present at time of enrollment

Prior allogeneic stem cell transplant within 6 months of starting treatment or patients with active GVHD requiring immunosuppression

Cannot have received: duvelisib or ruxolitinib (duvelisib, ruxolitinib)

Exception: if either agent was discontinued due to toxicity

Prior use of duvelisib or ruxolitinib if either agent was discontinued due to toxicity

Cannot have received: systemic anti-cancer therapy

Exception: localized RT as immediate prior therapy may be allowed with shorter washout after discussion with MSK PI; single agent ruxolitinib or duvelisib may be allowed without washout

Previous systemic anti-cancer therapy for TCL within 14 days of initiating study drug